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Serial Dexamethasone Suppression Tests in 
Simultaneous Panic and Depressive Disorders 
Leon Grunhaus, Pam Flegel, Roger F. Haskett, and John F. Greden 
Recent work suggests that the simultaneous occurrence of major depressive disorder 
(MDD) and panic disorder (PD) may be of relevance for clinical findings, therapeutic 
outcome, and prognosis. It is of interest to know whether or not this relevance extends 
to biological findings. We addressed this question through comparison of serial Dexa- 
methasone Suppression Test (DST) results in patients who had either MDD alone or 
simultaneous MDD and PD. We were unable to describe diflerences between the groups. 
Introduction 
Recent communications have stressed the frequent association of panic disorder (PD) and 
major depressive disorder (MDD) (Leckman et al. 1983a,b; Breier et al. 1984; Bueno et 
al. 1984; Weisman et al. 1984; Grunhaus et al. 1984,1985, 1986; Grunhaus and Birmaher 
1985). It appears that when PD combines with MDD,, a more severe disturbance may 
then be present; these patients may have (1) increased need for psychiatric treatments 
and hospitalizations, (2) poorer treatment outcome and prognosis, and (3) increased 
incidence of family psychopathology. It is then important to determine whether or not 
the combined condition of PD and MDD has biological characteristics that differentiate 
it from either disorder alone. The Dexamethasone Suppression Test (DST) has been 
extensively studied in MDD and also in PD or agoraphobia with panic attacks (Curtis et 
al. 1982; Liberman et al. 1983; Sheehan et al. 1983; Cottraux and Claustrat 1984; Avery 
et al. 1985; Coryell et al. 1985; Petterson et al. 1985; Roy-Byrne and Uhde 1985). 
Approximately 50% of MDD patients and less than 20% of PD patients will show DST 
nonsuppression. Thus, it is of interest to see whether or not the presence of PD in MDD 
patients has an impact on the suppressibility of the DST when compared to patients with 
MDD alone. Grunhaus et al. (1984, 1986) and Bueno et al. (1984) have reported on the 
DST results of patients with MDD and simultaneous PD compared to patients with MDD 
alone. They found similar rates of nonsuppression in both groups of depressed patients. 
Grunhaus et al. and Bueno et al. included both inpatients and outpatients in their studies 
and based their conclusions on a single diagnostic test. To clarify this point further, we 
studied an inpatient population with simultaneous PD and MDD and compared them to 
an age- and severity-matched group with MDD alone, using multiple timepoints for the 
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DST. The added anxiety diagnosis had no impact on the suppressibility of the DST of 
the depressed patients. Some interesting clinical features of the combined syndrome were 
found. 
Methods 
This study was conducted at the Clinical Studies Unit (CSU) for Affective Disorders, 
which is a 12-bed inpatient unit with an adjacent outpatient program specializing in 
research and treatment of affective disorders. We included only inpatients between the 
ages of 20 and 65 years. Our standard CSU evaluation consisted of a 1Cday drug-free 
period for the majority of patients, several clinical interviews, a structured diagnostic 
interview [Schedule for Affective Disorders and Schizophrenia (SADS) and SADS-Lifetime 
Version (SADS-L)], a thorough medical evaluation, and a diagnostic family interview. 
Comprehensive diagnoses were formulated based on Research Diagnostic Criteria (RDC) 
(Spitzer et al: D75). 
The study was designed to compare two groups of patients: those with simultaneous 
PD and MDD (simultaneous group) and those with only MDD (depressed group). The 
diagnosis of PD was based on the ratings on panic attacks in the current episode of illness 
obtained from the SADS interview. For inclusion into the simultaneous group, our 
first step was to determine if subjects met RDC criteria for MDD. Our next step was to 
determine if subjects met RDC criteria for PD: if so, we diagnosed both conditions 
regardless of whether subjects had MDD (this is a modification of written RDC criteria 
for MDD). None of the patients with MDD alone (depressed group) met diagnostic criteria 
for PD or agoraphobia, either for the current episode of illness or in their life history (as 
reported in the SADS-L). 
The patients in the simultaneous group were matched with patients from the depressed 
group for the following variables: (1) age within 5 years (2) adjusted Hamilton Rating 
Scale for Depression (A-HRSD) within 3 points (the A-HRSD was obtained by subtracting 
the psychic and somatic anxiety ratings), and (3) diagnosis of MDD endogenous subtype 
and nonendogenous subtype according to RDC. Other inclusion criteria for both groups 
were: (1) Hamilton Rating Scale for Depression (HRSD) (Hamilton 1960) of 12 or more 
(2) no technical exclusion criteria known to invalidate biological correlates (Carroll et 
al. 1981), (3) no other illness that could account for the panic attacks, (4) absence of 
pregnancy, and (5) informed consent for participation in research. Investigators and 
clinical raters were blind to research variables. 
The DST was performed using the standardized version of Carroll et al. (1981), giving 
1 mg of dexamethasone at 11:OO PM on day 1 and measuring blood samples at 4:00 and 
1l:OO PM on day 2. We matched only those who had at least three DSTs during their 
hospital stay. DSTs were considered nonsuppressive if either of the values of day 2 were 
above 5 pg/dl. Patients were considered to be nonsuppressors if they had any of the 
pretreatment DSTs above the cut-off of 5 Pg/dl. Plasma cortisol was assayed using a 
competitive protein-binding assay (Murphy 1967), which has been standardized for the 
lower ranges of plasma cortisol. The patients with simultaneous MDD and PD reported 
here are a subsample of those with longitudinal data of a previously reported study 
(Grunhaus et al. 1986). 
Patients were compared on the following variables: (1) HRSD and age-matching cri- 
teria; (2) baseline, midtreatment, and predischarge post-DST plasma cortisol using a cut- 
off point of 5 and absolute and log-transformed plasma cortisol values; (3) SADS and 
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SADS-L variables of social function, outcome of previous episode, number of previous 
episodes of depression, level of function in past 5 years, and Global Assessment Scale 
(GAS); and (4) a number of clinical variables and family history of affective disorders. 
Dichotomous variables were analyzed with the chi-square test, matched samples with a 
paired t-test, and unpaired clinical variables with a two-sample Student’s t-test. 
Treatment was prescribed by the attending psychiatrist as clinically indicated. Response 
to treatment was assessed with our standard method: (1) good response-those having a 
drop in their HRSD score of 50% or more and having a final HRSD of 10 or less; (2) 
partial response-whenever the HRSD dropped 50% or more but remained above 10; 
and (3) poor response-whenever responses 1 or 2 were not met. Treatment regimens 
were comparable between the groups. Treatment outcome variables will be described in 
detail elsewhere, as part of a larger sample of treated patients with MDD-PD (Grunhaus 
et al., in preparation). 
Results 
Sixteen inpatients with MDD and PD were matched with others with MDD alone. All 
of the patients were primary MDDs. The matching variables were similar for both groups 
and are presented in Table 1. As a cross-validation of the adequate matching of the 
severity of illness, the GAS was also similar in both groups (Table 1). Indicators of 
hypothalamus-pituitary-adrenal (HPA) function values (highest postdexamethasone plasma 
cortisol, log-transformed plasma cortisol, and number of nonsuppressors) in the two 
groups were not significantly different at baseline, midtreatment, or discharge. The process 
of normalization of the DST with treatment can be observed in Figure 1; the profile 
analysis at three time points--baseline, midtreatment, and discharge-did not reveal 
significant differences between the groups. 
Table 1. Clinical and DST Variables 
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‘Numerator MDD-PD group, denominator MDD only group. 
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‘NO SIGNIFICANT DIFFERENCE 
AT ANY TIME-POINT 
Figure 1. Baseline, midtreatment, and discharge values for the maximal postdexamethasone plasma 
cortisol values, HRSD, and A-HRSD in patients with MDD-PD or MDD only. Significance mea- 
sured by paired Student’s t--tests. 
The clinical variables were strikingly similar. The SADS ratings for outcome from 
previous episodes, highest level of function in past 5 years, social function, and number 
of outpatient treatments did not differentiate between the groups. A number of longitudinal 
variables (age at first episode of depression, previous suicide attempts, family history for 
affective disorders, and length of current episode) were similar in both groups. Interest- 
ingly, previous hospitalizations for depression and number of previous episodes of en- 
dogenous depression were more frequent, but not significantly different, in those with 
MDD-PD. The individual HRSD items, including those of psychic and somatic anxiety, 
did not differentiate between the groups; thus, the patients with PD and MDD were not 
more severely anxious. The correlations between total HRSD and A-HRSD with baseline 
postdexamethasone maximal cortisol values were highly significant in both groups (MDD- 
PD:r = 0.46, p = 0.00001; MDD:r = 0.43,~ = 0.00001). 
Discussion 
Our findings confirm previous reports by Gnmhaus et al. (1985) and Bueno et al. (1984) 
that HPA function is not different in MDD and MDD-PD patients. In our population of 
MDD and PD patients, the rate of nonsuppression (56%) was similar to that of the MDD 
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only patients (50%). This lack of differentiation persisted throughout the hospitalization 
and the process of normalization of the DST during treatment. The rate of nonsuppression 
at discharge was similar in both groups: approximately 20%. 
From a clinical perspective, both groups appeared to be very similar. The differences 
observed were with regard to the number of hospitalizations and previous episodes of 
MDD. Patients with PD and MDD had been hospitalized more often and also had a 
history of more frequent episodes of MDD. Even though these results did not reach 
statistical significance, probably due to the small sample, they may be an indication of 
a more severe course of illness, which is in line with other recent reports (Breier et al. 
1984; Weissman et al. 1984; Leckman et al. 1983a). Further indication of the possibly 
more severe quality of the combined condition comes from the difficulties these patients 
have remaining drug-free during our customary diagnostic and observation period. Twenty- 
five percent of the PD and MDD group could not reach the 2-week drug-free period, 
whereas all of the MDD only patients were able to do so. 
It appears then, that the hypothalamic-pituitary-adrenal (HPA) axis dysfunction, as 
measured through negative feedback loops with the DST, is very similar in MDD only 
patients and those with the simultaneous syndrome. Together with the findings of low 
nonsuppression rates in PD only patients, it is possible to suggest that the underlying 
physiopathology of PD does not have an impact on the HPA axis function as measured 
with the DST. These findings support the specificity of the DST with regard to anxiety 
conditions and, particularly, PD. 
Increased levels of adrenergic secretions (epinephrine , norepinephrine , MHPG , and 
DOPEG) in MDD patients who also have DST nonsuppression have been described by 
some authors (Barnes et al. 1983; Jimmerson et al. 1983), but not by others (Loo et al. 
1985). Similarly, increased adrenergic tone has been proposed as central to anxiety 
conditions (Redmond and Huang 1979), and some authors have found elevated adrenergic 
products in panic conditions (Ko et al. 1983; Cameron et al. 1984). It is then possible 
to suggest that in the presence of both psychopathologies, MDD and PA, the rate of 
nonsuppression would be higher. As evidenced by our results, we found no difference 
in the rates of DST nonsuppression in our group of patients. 
Even though it appears that the DST results are similar in patients with either MDD 
or simultaneous MDD and PA, both at pretreatment and discharge time points, it is yet 
unclear whether or not any differences may be identified in prognosis. In follow-up studies, 
it would be of interest to test the hypothesis that the simultaneous syndrome of MDD 
and PA, and by inference to DST nonsuppression associated to a hyperadrenergic state, 
will have a worse outcome than MDD alone. As mentioned in our introduction, some 
outcome studies (Van Valkenburg et al. 1984) already lend support to the clinical aspects 
of this hypothesis. We are currently engaged in a study collecting data to test the biological 
aspects of it. 
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